3 news items
4 Analysts Assess Teva Pharmaceutical Indus: What You Need To Know
TEVA
30 May 24
.
Breaking Down Analyst Ratings: A Detailed Examination
The standing of Teva Pharmaceutical Indus among financial experts is revealed through
Teva Pharmaceutical Indus's Options Frenzy: What You Need to Know
TEVA
22 May 24
that the underlying stock may be overbought.
Next earnings are expected to be released in 70 days.
Expert Opinions on Teva
Teva and mAbxience Announce Strategic Global Licensing Agreement for Oncology Biosimilar Candidate
TEVA
4 Apr 24
regulatory bodies, including the FDA, EMA, and others. Furthermore, as a global biopharmaceutical expert, mAbxience specializes in Contract Development
- Prev
- 1
- Next